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Abstract
Progestins provide safe, effective and cheap options for contraception as well as the treatment of a variety of
gynaecological disorders. Episodes of irregular endometrial bleeding or breakthrough bleeding (BTB) are a major unwanted
side effect of progestin treatment, such that BTB is the leading cause for discontinued use of an otherwise effective and
popular medication. The cellular mechanisms leading to BTB are poorly understood. In this study, we make the novel
finding that the large, dilated, thin walled vessels characteristic of human progestin-treated endometrium include both
blood and lymphatic vessels. Increased blood and lymphatic vessel diameter are features of VEGF-D action in other tissues
and we show by immunolocalisation and Western blotting that stromal cell decidualisation results in a significant increase in
VEGF-D protein production, particularly of the proteolytically processed 21 kD form. Using a NOD/scid mouse model with
xenografted human endometrium we were able to show that progestin treatment causes decidualisation, VEGF-D
production and endometrial vessel dilation. Our results lead to a novel hypothesis to explain BTB, with stromal cell
decidualisation rather than progestin treatment per se being the proposed causative event, and VEGF-D being the
proposed effector agent.
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Introduction
Progestins provide safe, effective and cheap options for
contraception as well as the treatment of a variety of gynaecolog-
ical disorders [1]. Although originally developed as a contracep-
tive, the levonorgestrel-releasing intra-uterine system (LNG-IUS) is
also highly effective at controlling excessive menstrual blood loss in
the majority of women treated [2]. Progestins are also used
clinically in a number of other situations such as to provide relief
from the symptoms of endometriosis by suppressing growth of the
ectopic endometrium [3]. However, episodes of irregular endo-
metrial bleeding or breakthrough bleeding (BTB) are a major
unwanted side effect of progestin treatment, such that BTB is the
leading cause for discontinued use of an otherwise effective and
popular medication [4,5]. Endometrial breakthrough bleeding is
defined as any irregular or unpredictable bleeding that is not part
of the normal menstrual process. Unlike menstrual bleeding,
which occurs primarily from the spiral arterioles in response to
falling levels of estrogen and progesterone [6], BTB occurs from
the endometrial capillaries and smaller vessels [7].
Understanding of the cellular mechanisms underlying BTB
remains elusive because of both the range of hormonal conditions
under which it can occur and the high degree of variability
between women in terms of their endometrial response to
exogenous hormones and their susceptibility to BTB. Thus, while
administration of exogenous progestins will increase the incidence
of BTB, the link between hormones and BTB is not direct.
Numerous studies over the past 20 years have been undertaken
with the aim of developing a better understanding of the local
endometrial mechanisms responsible for BTB. Some of factors
that have been proposed as playing a role in BTB include
endometrial epithelial integrity [8], altered MMP levels [9],
altered leucocyte populations [10], reduced vascular pericyte
coverage [11,12], and increased vascular fragility [13]. Despite this
work, widespread consensus as to mechanisms that might be
responsible for BTB does not exist yet within the field.
Decidualisation is a hormonally regulated cellular differentia-
tion process that occurs in the endometrial stroma of most
mammals prior to and during placentation. It is accompanied by
significant vascular remodelling of both blood and lymphatic
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30916vessels [14,15] as part of the process of ensuring an adequate blood
supply to the placenta. In humans, decidualisation commences
during the mid-late secretory phase under the influence of luteal
progesterone regardless of whether embryo implantation has
occurred. However, if implantation does not occur, circulating
progesterone levels drop rapidly and the decidualised tissue is shed
a few days later during menstruation.
Endometrium exposed to progestins undergoes a well char-
acterised series of morphological changes that includes stromal cell
pseudo-decidualisation, epithelial cell regression [16] and the
appearance of abnormally dilated and thin-walled endometrial
vessels [7,17,18,19,20,21,22]. While it has been proposed that the
abnormally dilated, thin walled vessels found in progestin-exposed
endometrium may contribute to BTB through increased vascular
fragility [13], there is currently a lack of information character-
izing these vessels, and little insight as to the mechanisms behind
their formation. If these dilated, thin-walled vessels do play a role
in BTB, a better understanding of how they are formed may assist
in identifying new avenues for treating this troublesome side-effect
of progestin treatment.
The overall aim of this study was to investigate potential
mechanisms by which progestin administration results in the
formation of abnormally dilated and thin-walled endometrial
vessels.
We were able to demonstrate that a significant proportion of the
dilated, thin walled vessels in progestin treated human endome-
trium are lymphatics and not blood vessels. Both lymphatic and
blood vessels show marked increases in diameter following
progestin treatment, while lymphatics in the functional layer are
the only vessels to show a moderate increase in number. Increased
blood and lymphatic vessel diameter, but not number, are features
of VEGF-D action in other tissues [23] and we show by
immunolocalisation and Western blotting that stromal cell
decidualisation results in a significant increase in VEGF-D protein
production, particularly of the biologically active 21 kD form. We
then use a NOD/scid mouse model with xenografted human
endometrium to show that progestin treatment causes decidualisa-
tion, VEGF-D production and endometrial vessel dilation. Our
results lead to a novel hypothesis to explain BTB, with stromal cell
decidualisation rather than progestin treatment per se being the
proposed causative event, and VEGF-D being the proposed
effector agent.
Results
Endometrial Blood and Lymphatic Vessels have Increased
Diameters in Women Exposed to Intra-Uterine
Levonorgestrel
Full-thickness endometrial sections from women with heavy
menstrual bleeding who had either been treated with a
levonorgestrel intrauterine system (LNG-IUS) (N=16) or who
were untreated controls (N=16) [22], were immunostained with
antibodies to CD31 (labels both lymphatic and blood endothelial
cells) or D2-40 (labels lymphatic endothelial cells only). Blood
vessel counts were made from CD31 immunostained sections by
subtracting the D2-40 immunostained vessel count made on a
serial section. Endometrial blood and lymphatic vessels were
readily identifiable in all sections following immunostaining (Fig. 1).
Most of the microvessels were of normal appearance in both the
LNG-IUS treated tissue and the controls. However, in the
levonorgestrel treated tissue, but not the control tissue, large, thin
walled vessels were also observed. Immunohistochemistry with
D2-40 revealed that some of these vessels were lymphatics. In
LNG-IUS treated tissue, the large or dilated lymphatic and blood
vessels appeared to be mostly located in the functional layer,
although a few were also seen in the basal layer.
Using 2-way ANOVA, the vessel cross sectional area of the 5
largest blood vessels was significantly greater in endometrium from
Figure 1. Progestin-induced endometrial blood and lymph vessel dilatation. Enlarged blood and lymphatic vessels are present in the
endometrium of women treated with LNG-IUS prior to hysterectomy for heavy menstrual bleeding. (A–B) Untreated control samples. (C–D) LNG-IUS
treated samples. Sections have been immunostained with CD31 (A, C), which labels both blood and lymphatic endothelial cells, or D2-40 (B, D), which
labels lymphatic endothelial cells only. Black arrows: blood vessels.
doi:10.1371/journal.pone.0030916.g001
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12.693, P=0.001) (Fig. 2A). Tukey’s posthoc tests showed that this
observation was true in the functional layer (Control: 1.06
10
2363.8610
24 mm
2; LNG-IUS: 3.5610
2369.7610
24 mm
2;
P=0.026) but not the basal layer (Control: 1.2610
2363.76
10
24 mm
2; LNG-IUS: 4.6610
2361.4610
23 mm
2; P=0.165). A
similar analysis of the five largest lymphatic vessels showed a
significant increase in area for LNG-IUS versus control treated
tissues (F(1,60)=19.569, P=0.001) (Fig. 2B). This was the case in
both the functional layer (Control: 6.4610
2462.3610
24 mm
2;
LNG-IUS: 3.8610
2369.8610
24 mm
2; P=0.01) and also the
basal layer (Control: 1.0610
2363.1610
24 mm
2; LNG-IUS:
3.2610
2368.8610
24 mm
2 P=0.021).
In contrast to vessel cross sectional areas, there was no
difference in endometrial blood vessel density (F(1,53)=1.08,
P=0.304 or lymph vessel density (F(1,63)=2.384, P=0.128)
between control or LNG-IUS treated tissues (Fig. 3). Also, there
was no overall significant difference in vessel density between the
functional layer vs. the basal layer for blood vessels (Functional
Layer: Control: 4266.9 vessels/mm
2; LNG-IUS: 45610.7
vessels/mm
2 Basal Layer: Control: 3164.8 vessels/mm
2; LNG-
IUS: 3968.6 vessels/mm
2;F (1,53)=0.342, P=0.562) or lymphatics
(Functional Layer: Control: 962.5 vessels/mm
2; LNG-IUS:
2364.8 vessels/mm
2 Basal Layer: Control: 2465.0 vessels/mm
2;
LNG-IUS: 2062.6 vessels/mm
2;F (1,63)=2.779, P=0.101).
Human Endometrial Stromal Cells Show Increased
Expression of VEGF-D Following Decidualisation
Increased blood and lymphatic vessel diameters are a
recognised consequence of elevated tissue expression of VEGF-D
[23]. Immunohistochemical and Western blotting techniques were
used to investigate whether VEGF-D protein levels are increased
in decidualised endometrial stromal cells. Focal areas of pre-
decidualisation were common in endometrium treated with LNG-
IUS (N=16) but not in endometrium from controls (N=16). Pre-
decidual cells showed intense immunostaining for VEGF-D (Fig. 4)
but not VEGF-C (data not shown). There was a clear increase in
VEGF-D immunostaining intensity in pre-decidual cells compared
to non-decidualised stromal cells in areas where these two cell
types appeared together (Fig. 4A and 4C).
To further explore whether the process of decidualisation results
in elevated expression of VEGF-C and VEGF-D protein, Western
analysis was performed on human endometrial stromal cells before
and after decidualisation in vitro (N=5 samples). Human
endometrial stromal cells showed evidence by Western analysis
for increased expression of both VEGF-C and VEGF-D after
decidualisation in vitro (Fig. 5A,5 B and Fig. S1). Up to seven
VEGF-D polypeptides were detected including 53, 44, 41, 29/31
and 21 kD [24]. There was a significant increase in VEGF-D
expression in decidualised versus non-decidualised cells
(F(1,16)=22.2, P=0.001) with a significant variation among
different isoforms (F(3,16)=4.38, P=0.02). Paired T-tests were
significant after Bonferoni correction for the 53 kD (3.5-fold
increase in relative density, P=0.002) and 21 kD (8.2-fold increase
in relative density, P=0.005) isoforms, but not for the 41 (P=0.05,
Figure 2. Increased blood and lymphatic vessel area after
progestin exposure. Blood and lymphatic vessel cross sectional areas
are increased in endometrium from women treated with LNG-IUS prior
to hysterectomy for heavy menstrual bleeding. (A) The mean area of the
five largest blood vessels in the functional layer and the basal layer in
untreated control (white bars) and LNG-IUS treated (grey bars)
endometrium. (B) The mean area of the five largest lymphatic vessels
in the functional layer and the basal layer of untreated control (white
bars) and LNG-IUS treated (grey bars) endometrium. Columns represent
means 6 SE. *, P,0.05.
doi:10.1371/journal.pone.0030916.g002
Figure 3. Endometrial blood and lymphatic vessel density after
progestin exposure. Blood and lymphatic vessel densities do not
change in endometrium from women treated with LNG-IUS prior to
hysterectomy for heavy menstrual bleeding. (A) Vascular density of
blood vessels in untreated control (white bars) and LNG-IUS treated
(grey bars) samples of the functional layer and the basal layer. (B)
Lymphatic vessel density in untreated and LNG-IUS treated endometrial
samples. Columns represent means 6 SE. *, P,0.05.
doi:10.1371/journal.pone.0030916.g003
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correction) and 29/31 kD (P=0.26) isoforms. The increase in the
21 kD isoform is of particular relevance as following proteolytic
processing this is the most biologically active isoform with the
highest affinity for VEGF receptor-3 (VEGFR-3), which in the
adult is found on lymphatic endothelial cells [25]. VEGF-C
protein was detected as 58, 43, 29/31 kD polypeptides [26].
Densitometry showed there was a significant increase in VEGF-C
expression in decidualised versus non-decidualised cells by 2-way
mixed ANOVA (F(1,16)=25.7, P=0.001), as well as a significant
variation among different isoforms (F(3,16)=4.93, P=0.013).
Paired T-tests for individual isoforms failed to reach significance
after Bonferoni correction (Note: to reach significance after the
Bonferoni correction, a P-value of 0.0125 is required: 58 KD:
P=0.024, 43 kD: P=0.21, 29/31 kD: P=0.023; 21 kD: P=0.50;
Fig. 5C).
Exogenous Progestin Produces a Pre-decidual Response
in Human Endometrial Xenografts Resulting in VEGF-D
Expression and Increased Lymphatic Vessel Diameters
To further explore the role of exogenous progestin in causing
lymphatic vessel dilatation through decidualisation-dependent
expression of VEGF-D, a human endometrial xenograft model
in NOD/scid mice was utilised. A total of n=4 human samples
were subdivided and grafted into NOD/scid mice that were
subsequently treated with estradiol valerate only, or estradiol
valerate and medroxyprogesterone acetate (MPA). The estrogen
component of this treatment maximizes xenograft establishment,
vascularisation and survival, and the progestin recreates the
hormonal status that exists in women using progestin contra-
ceptives.There was a 100% recovery of graft tissue at the end of
the experimental period. There were no obvious macroscopic
differences between the treatment groups with all grafts becoming
encapsulated by extracellular matrix. The endometrial vasculature
was composed of both blood and lymphatic vessels which were
predominantly of human origin (9263%) with a small number of
murine vessels also infiltrating the endometrial tissue (863%)
(Fig. 6A and 6B). All subsequent analysis of blood and lymphatic
vessels only included vessels that exhibited positive immunostain-
ing with human anti-CD31 antibody. The endometrial xenografts
that received estrogen-only contained stromal cells that were
densely packed and fibroblast-like in appearance while the
glandular epithelium was cuboidal or columnar (Fig. 6C – H&E
staining). In contrast, the progestin-treated xenografts exhibited
pre-decidualised stromal cells with flattened glandular epithelial
cells (Fig. 6D – H&E staining). To confirm that decidual cells in
progestin treated xenografts expressed VEGF-D, immunostaining
was performed. VEGF-D immunostaining was intense in decid-
ualised tissue in xenografts (Fig. 7), and was also apparent in
epithelial cells.
Blood and lymphatic vessel density and cross sectional area
were evaluated in progestin-treated (n=4) and control xenografts
(n=4) following immunostaining with antibodies to CD31 and
D2-40. There was a significant increase in cross-sectional area of
the 5 largest lymph vessels in the progestin treated xenografts
(4.6610
2465.0610
25 vessels/mm
2) when compared to the
estrogen-only treated xenografts (1.1610
2361.0610
24 vessels/
mm
2)t (6)=25.873, P=0.001) (Fig. 8D). Xenografts treated with
progestin for 4 weeks (245635.9 vessels/mm
2) had significantly
reduced blood vessel density when compared to xenografts that
received estrogen-only (406644.3 vessels/mm
2) for the same
length of time (t(6)=2.848, P=0.029) (Fig. 8A). There was no
difference in lymph vessel density between treatment groups
(estrogen-only: 2969.2 vessels/mm
2; progestin: 2363.1 vessels/
mm
2;t (6)=0.619, P=0.559) (Fig. 8B). There was also no
significant difference in the cross-sectional area of the 5 largest
Figure 4. VEGF-D immunostaining in endometrial decidual cells. Distinct VEGF-D immunostaining (brown) is present in pre-decidual cells of
endometrium from women treated with LNG-IUS prior to hysterectomy. (A) Micrograph illustrating difference in VEGF-D immunostaining (brown)
intensity in stromal pre-decidualised cells (pd) compared to non-decidualised cells (nd). (B) Higher power image of pre-decidualised stromal cells
showing VEGF-D immunostaining in brown. (C) Higher power image of non-decidualised stromal cells showing reduced VEGF-D immunostaining. (D)
Isotype matched negative control. Black arrow: blood vessel. (sections are lightly counterstained with haematoxylin to identify cell nuclei in blue).
doi:10.1371/journal.pone.0030916.g004
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8.7610
2463.0610
24 vessels/mm
2; progestin: 2.8610
236
1.1610
23 vessels/mm
2;t (6)=21.681, P=0.179) (Fig. 8C).
Discussion
In this study, we make the novel finding that the large, dilated
vessels characteristic of progestin-treated endometrium include
both blood and lymphatic vessels (Fig. 1). That both blood and
lymphatic vessels exhibit abnormal morphology and dilatation in
response to progestin is consistent with a regulatory mechanism
common to both vessels types. Evidence for such a mechanism
comes from studies evaluating the therapeutic potential of human
VEGF family members using adenoviral gene transfer in rabbit
hind limb skeletal muscle [23]. The VEGF family of angiogenic
and lymphangiogenic peptides includes VEGF-A, VEGF-B,
VEGF-C, VEGF-D and placental growth factor [27]. VEGF-C
and VEGF-D act by binding and activating the tyrosine kinase
receptors VEGF receptor-2 (VEGFR-2) and VEGFR-3, which in
the adult are found predominantly on blood and lymphatic
endothelial cells, respectively [28,29]. VEGF-C and VEGF-D
differ from other members of the mammalian VEGF family due
to the presence of pro-peptides at both the N- and C-termini of
the conserved VEGF homology domain [26]. Cleavage of the
pro-peptides by proteases such as plasmin modulates bioactivity
of both molecules, increasing affinity for both VEGFR-2 and
VEGFR-3 [25,26,30]. In the rabbit hind limb skeletal muscle
study, both VEGF-A and the proteolytically processed 21 kD
form of VEGF-D caused a remarkable enlargement of micro-
vessels, however, while VEGF-A only affected blood vessels,
VEGF-D enlarged both blood and lymph vessels [23]. VEGF-A
also moderately increased capillary density, whereas VEGF-D
induced angiogenesis was more diffuse. VEGF-D has also been
shown to induce vessel enlargement in mouse hind limb [23,31],
rat cremaster muscle [32], pig heart [33], mouse skin [34] and
mouse uterine horn [35]. The remarkable similarity in the
changes to the blood and lymph microvessels in our study and
those previously published provided the impetus to further
investigate a role for VEGF-D in the progestin treated human
endometrium.
Progestin-treated endometrium usually exhibits areas of decid-
ualisation, especially in the first few months of exposure before
endometrial regression has occurred [17,18,36]. However, in
contrast to the normal menstrual cycle, these decidual cells are
maintained by the exogenous progestin for a relatively long period
of time in the absence of implantation or placentation. Given that
decidual cells play a central role in placentation, it is reasonable to
speculate that the pathological vascular changes seen in progestin-
affected endometrium are the consequence of normal vascular
remodelling for placentation that has become defective through a
lack of implantation. The observation that BTB occurs with nearly
all types of progestin is consistent with the hypothesis that it is the
Figure 5. VEGF-D protein in endometrial decidual cells. Western analysis of vascular endothelial cell growth factor-C (VEGF-C) and VEGF-D
peptide expression in primary cultures of human endometrial stromal cells (HESC). Panels A and B show representative data from 3 samples. Panels C
and D show combined densitometry data from all 5 samples. (A) VEGF-C peptide expression (58, 41, 29/31 and 21 kD) in HESC (ND) and decidualised
HESC (Dec). (B) VEGF-D peptide expression (53, 41, 29/31 and 21 kD) in HESC and decidualised HESC. (C–D) Densitometry of VEGF-C and VEGF-D
peptide expression. White bars representing control non-decidualised HESC and black bars representing decidualised HESC. Columns represent
means 6 SE; * P,0.05.
doi:10.1371/journal.pone.0030916.g005
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30916Figure 6. Human endometrial xenografts in NOD/scid mice. Representative micrographs of human endometrial xenografts taken from NOD/
scid mice after 6 weeks growth at a subcutaneous site. (A) A mixture of human and mouse vessels at the edge (capsule) of the xenograft shown by
double immunostaining with anti-human CD31 (brown, black arrow) and anti-mouse CD31 (blue, white arrow). Note the vessel of mixed human and
mouse origin (grey arrow). (B) The central portion of the xenograft populated almost exclusively with vessels of human origin (double
immunostaining with anti-human CD31 in brown and anti-mouse CD31 in blue). (C) Routine haematoxylin and eosin stained xenografts treated with
estradiol valerate developed densely packed fibroblast-like stromal cells and cuboidal to columnar epithelial cells. (D) Routine haematoxylin and eosin
stained xenografts grafts treated with MPA displayed pre-decidualised stromal cells with flattened epithelial cells. ep: epithelium, g: glands, m:
myometrium, pd: pre-decidual stroma, s: stroma.
doi:10.1371/journal.pone.0030916.g006
Figure 7. VEGF-D immunostaining of xenograft decidual cells. Representative micrographs of human endometrial xenografts from NOD/scid
mice treated with estradiol valerate (A,B) or medroxyprogesterone acetate (C,D). Serial sections were stained with haematoxylin and eosin (A,C) or
immunostained with VEGF-D (B,D). Inset in (B): Isotype matched negative control. Note the pre-decidual cells in MPA-treated sections. ep: epithelium,
g: glands, pd: pre-decidual stroma, s: stroma.
doi:10.1371/journal.pone.0030916.g007
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than a direct effect of the progestins on blood vessels. In a mouse
model of BTB it has been shown that endometrial breakdown
following prolonged progestin treatment is dependent on decid-
ualisation [37]. Although this study does not link decidualisation
directly to a mechanism that causes vascular dilatation, it points
towards a relationship between decidualisation and BTB.
While VEGF-D is a highly plausible candidate for causing the
microvascular changes seen in progestin-exposed endometrium,
decidual cells have upregulated expression of many other proteins,
including connexin 43, prolactin, IL-6 and VEGF-A [38]. It is
possible that one or several of these other agents may play
contributory roles in causing BTB. We have previously investi-
gated VEGF-A expression by immunohistochemistry in decid-
ualised and non-decidualised endometrial stromal cells of women
with BTB following progestin-only contraception and found no
difference [39], despite the fact that it is up-regulated in in vitro
decidualised stromal cells [38].
While the current study establishes a potential mechanistic link
between progestins, decidualisation and endometrial microvessel
dilatation, the link between dilated endometrial vessels and BTB
remains more speculative. Further, if a relationship between
dilated endometrial vessels and BTB does exist, we would assume
that it is the blood vessels and not the lymphatic vessels that are the
primary cause. There are several published studies that do support
a link between vessel dilatation and BTB. Most significantly,
dilated endometrial vessels, which are a common occurrence with
systemic or intrauterine progestin exposure, have been shown to
demonstrate increased fragility in hysteroscopic studies [13,19,40].
Additionally, it has been shown that perivascular a-smooth muscle
actin (aSMA) is reduced around the endometrial vessels of
progestin users with BTB compared to those with no bleeding
problems [11]. Reduced aSMA indicates a loss of perivascular
support cells, specifically pericytes and vascular smooth muscle
cells, a process which could be expected to contribute significantly
to increased vascular fragility and BTB. Other groups have also
reported a reduction in endometrial vessel aSMA coverage
following exposure to the progestin levonorgestrel [12]. This
study suggested that time-dependent changes in blood vessel
number, area, density and maturation following exposure to LNG-
IUS may explain the early transient increase in BTB. In a further
study examining the link between BTB and endometrial vessel
structure, it was reported that in women with BTB after 12 months
of progestin treatment, significantly greater numbers of enlarged,
Figure 8. Progestin effects on xenograft vessel density and area. Blood vessel density decreases and lymphatic vessel cross sectional vessel
area increases in human endometrial xenografts treated with medroxyprogesterone acetate (MPA). (A) Blood vessel density and (B) lymphatic vessel
density of untreated (E only) and treated (MPA) xenografts. (C) Blood vessel and (D) lymphatic vessel cross sectional area of E only and MPA treated
xenografts. Bars represent means 6 SE. * P,0.05.
doi:10.1371/journal.pone.0030916.g008
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compared with non-bleeding sites [41]. These authors suggested
that chronic over expression of endometrial Tissue Factor (TF) at
the bleeding sites might be promoting aberrant angiogenesis,
resulting in the enlarged and fragile vessels with increased risk of
bleeding.
In the current study we used a xenograft model to investigate
the progestin-related changes to human endometrium caused by
medroxyprogesterone acetate treatment in vivo. Our results parallel
a recent study that used LNG to treat human endometrial
xenografts for 4 weeks in SCID mice [42]. In both studies, 4 weeks
of progestin exposure caused heterogeneous decidualisation and
an increase in vessel diameter in subcutaneous endometrial
explants. Additionally, both models retained a greater than 90%
presence of human vessels within the xenograft with minimal
invasion of host vasculature [43]. The similar observations from
these 2 independent studies confirm the utility of the xenograft
model for studying human endometrial microvascular function.
The current study identifies both decidual cells and VEGF-D as
potential targets for development of therapies for BTB. If decidual
derived VEGF-D is the agent responsible for BTB, then a number
of interventions might be possible. These include developing
progestins that minimise or avoid decidualisation, developing
agents that block progestin-induced decidualisation, and using
inhibitors of VEGF-D to prevent endometrial microvascular
dilatation.
Despite BTB having been a significant clinical problem for
many years, advances in understanding the mechanisms that cause
BTB have been limited. The lack of a readily available animal
model that reliably replicates progestin-induced BTB is probably
the single most critical issue responsible for this lack of progress.
The absence of an accepted model means that mechanistic studies
can only be performed in humans, which limits significantly the
research that can be undertaken. The xenograft model used the
current study does not exhibit BTB, despite replicating many of
the changes seen in human endometrium exposed to progestins.
Future progress in understanding BTB is most likely to come from
a combination of indirect mechanistic studies supported by
observational and correlational data from human subjects with
BTB.
In conclusion, we have identified dilated lymphatics in progestin
exposed human endometrium from women with BTB, which in
conjunction with dilated blood vessels identifies VEGF-D as a
potential causative agent. Further studies show that VEGF-D
expression increases as endometrial stromal cells undergo
decidualisation, and that this chain of events can be replicated
in human endometrial xenografts in NOD/scid mice treated with
progestin. Taken together these data implicate decidual cell-
derived VEGF-D as a causative factor in progestin-induced BTB.
Materials and Methods
Human samples and specimen collection
Fixed and wax embedded human uterine tissue blocks from a
previously published study [22] were obtained from women that
had been exposed to LNG-IUS as treatment for heavy menstrual
bleeding. Briefly, women who opted for a hysterectomy due to
continued heavy menstrual bleeding following standard treatment
options, were randomly allocated into LNG-IUS (n=16, mean age
38.6 years) or control groups (n=16, mean age 39.9 years). LNG-
IUS were in place for up to 156 days prior to surgery. For the
xenograft study, uterine biopsies were obtained following written
informed consent (this work was approved by Southern Health
Human Research and Ethics Committee under Project
No. 08176B) from 4 patients aged 48.761 year undergoing
hysterectomy for prolaspe or fibroids. Each sample was cut down
to the endometrial myometrial boarder and divided into 8 grafts
approximately 16160.5 cm in size.
Animals and Hormone Treatments
For xenograft studies, NOD/SCID female mice (n=32; 6–8
weeks) received a single graft in a pocket created on the right side
of the back flank (This work was carried out in accordance with
the Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes (2004) and approved by Monash Medical
Centre Animal Ethics Committee A, approval No. 2008/14).
Following closure of the wound site, mice received 1 mg1 7 b-
estradiol valerate in oil (subcutaneous) every fourth day until
experiment completion. After two weeks of graft establishment,
mice were divided into two groups and received a subcutaneous
silastic tube implant [44]. The 17b-estradiol valerate group
(Control) received an empty implant while the medroxyprogester-
one acetate (MPA-Progestin) group received an implant contain-
ing 20 mg of MPA. Progestin treatment was continued for 4 weeks
until graft harvest and fixation.
Sample collection and Immunohistochemistry
Patient samples and xenografts were formalin fixed and paraffin
embedded for immunohistological analysis. Tissue sections (5 mm)
mounted on silane coated slides were dewaxed and rehydrated.
Following antigen retrieval, endogenous peroxide block and
protein block, immunolocalisation of human vascular endothelial
cells (CD31: Clone JC 70A, Dako Cytomation, CA, USA,), human
lymphatic endothelial cells (anti-Podoplanin: Clone D2-40, Signet
Laboratories, MA, USA) [45], mouse vascular endothelial cells
(CD31: #553370, BD Pharmingen, NJ, USA) and human VEGF-
D( #AF469, R&D Systems MN USA) was performed as
previously described [35]. Using a 206 objective lens, the five
largest vessels within the endometrial component of the tissue were
identified and measured in mm
2 using the Analytical Imaging
System (AIS) (Imaging Research Inc. GE Healthcare Bio-Sciences,
NSW, Australia). We found this approach to be a simple and
statistically robust morphometric method for objectively demon-
strating the existence of the abnormally dilated and thin-walled
vessels found in progestin-exposed endometrium.In xenograft
samples, vessel density was determined by calculating the average
number of vessels from 4 separate endometrial areas. Statistical
analysis was performed using SPSS for Windows, Version 11.0.0
(SPSS Inc., Chicago, IL, USA). Vessel cross sectional area and
vessel density of the functional layer and basal layer vessels in the
endometrium of women +/2 LNG-IUS was determined by 2-way
ANOVA on logged data followed by Tukeys HSD post hoc
analysis. Statistical analysis of xenograft +/2 MPA vessel density
and diameter was determined by Student t test. Values are
presented as mean 6 SE unless otherwise stated. A p value ,0.05
was considered significant.
Western Blotting
Primary isolated human endometrial stromal cells (from n=5
endometrial biopsies) were decidualised following incubation with
estradiol 17b (10
28 mol/l) and progesterone (10
27 mol/l) as
previously described [46]. Protein from cell lysates (30 mg) were
resolved on a 4–12% NuPAGE gel (Invitrogen Corporation; CA,
USA). Following transfer to PVDF membranes, proteins were
probed for VEGF-C (1:200; AF286 R&D Systems; MN, USA),
VEGF-D (1:200; AF752 R&D Systems) or b-actin (1:4000; Sigma
Aldrich; NSW, Australia) overnight at 4uC. Signal was enhanced
with fluorescent secondary antibodies (1:20,000; AlexaFluor 680
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Membranes were scanned and densitometry determined by the
OdysseyH Infrared Imaging System (LI-COR Biosciences). The
relative densitometry for each peptide band was normalised to the
b-actin and expressed as a percentage of b-actin. Densitometry
data from VEGF-C and VEGF-D western blots were analysed
using a 2-way Mixed ANOVA followed by posthoc analysis using
paired T-tests with Bonferoni corrections to correct for multiple
comparisons.
Supporting Information
Figure S1 Representative western blots of (A) VEGF-C and (B)
VEGF-D protein expression in primary cultures of decidualised
(Dec) and non-decidualised (ND) human endometrial stromal
cells. White arrows indicate the reported isoforms including the C-
VHD-N full length receptor (VEGF-C: 58 kD; VEGF-D: 53 kD;
dimers at 105 kD), the VHD-N terminal (doublet, 29/31 kD), and
the VHD (21 kD). Other bands may be alternatively processed
forms including heterodimers, trimers and dimers, some of which
also exhibit changes associated with decidualisation (black arrows).
(TIF)
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